Literature DB >> 7759889

Increased cell-associated IL-8 in human exudative and A23187-treated peripheral blood neutrophils.

D B Kuhns1, J I Gallin.   

Abstract

IL-8 is a potent neutrophil chemoattractant that has been detected in high concentrations at acutely inflamed sites in vivo. Many cell types, including peripheral blood neutrophils, produce IL-8 that can be released by a variety of pro-inflammatory stimuli. However, the functional importance of neutrophil IL-8 during exudation is not yet known. We now report that neutrophils, harvested from skin lesions on the forearms of normal human volunteers (exudative neutrophils), expressed 100-fold higher levels of cell-associated IL-8 and spontaneously released up to 50-fold more IL-8 than freshly isolated peripheral blood neutrophils from the same donor. Furthermore, cell-associated IL-8 in peripheral blood neutrophils increased 20-fold during incubation at 37 degrees C in vitro and was increased over 200-fold after treatment with the Ca2+ ionophore A23187. More than 35% of the cell-associated IL-8 could be released by stimulation with either Ca2+ ionophore A23187 or phorbol myristate acetate. IL-8 was localized by sucrose gradient centrifugation to a subcellular fraction of heterogeneous, light membranous organelles. The accumulation of IL-8 within these organelles is inhibited by cycloheximide but not actinomycin D, suggesting that IL-8 accumulation is under translational, rather than transcriptional control. These studies indicate that peripheral blood neutrophils are capable of synthesis of large amounts of IL-8. Subsequent release of IL-8 during exudation may regulate neutrophil migration into sites of inflammation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7759889

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Editorial: will the real neutrophil please stand up?

Authors:  Kol A Zarember; Douglas B Kuhns
Journal:  J Leukoc Biol       Date:  2011-12       Impact factor: 4.962

2.  Presence of high levels of leukocyte-associated interleukin-8 upon cell activation and in patients with sepsis syndrome.

Authors:  C Marie; C Fitting; C Cheval; M R Losser; J Carlet; D Payen; K Foster; J M Cavaillon
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

Review 3.  Neutrophils at work.

Authors:  William M Nauseef; Niels Borregaard
Journal:  Nat Immunol       Date:  2014-07       Impact factor: 25.606

4.  TNF-α induces CXCL1 chemokine expression and release in human vascular endothelial cells in vitro via two distinct signaling pathways.

Authors:  Huey-ming Lo; Tsung-hsuan Lai; Chih-hung Li; Wen-bin Wu
Journal:  Acta Pharmacol Sin       Date:  2014-02-03       Impact factor: 6.150

Review 5.  Signal relay during chemotaxis.

Authors:  G L Garcia; C A Parent
Journal:  J Microsc       Date:  2008-09       Impact factor: 1.758

6.  Effect of iron overload from multi walled carbon nanotubes on neutrophil-like differentiated HL-60 cells.

Authors:  Yosuke Tabei; Hiroko Fukui; Ayako Nishioka; Yuji Hagiwara; Kei Sato; Tadashi Yoneda; Tamami Koyama; Masanori Horie
Journal:  Sci Rep       Date:  2019-02-18       Impact factor: 4.379

7.  Vascular endothelial growth factor induces CXCL1 chemokine release via JNK and PI-3K-dependent pathways in human lung carcinoma epithelial cells.

Authors:  Huey-Ming Lo; Jiunn-Min Shieh; Chih-Li Chen; Chih-Jen Tsou; Wen-Bin Wu
Journal:  Int J Mol Sci       Date:  2013-05-10       Impact factor: 5.923

8.  Regulation by anti-inflammatory cytokines (IL-4, IL-10, IL-13, TGFbeta)of interleukin-8 production by LPS- and/ or TNFalpha-activated human polymorphonuclear cells.

Authors:  C Marie; C Pitton; C Fitting; J M Cavaillon
Journal:  Mediators Inflamm       Date:  1996       Impact factor: 4.711

9.  Rationale and Means to Target Pro-Inflammatory Interleukin-8 (CXCL8) Signaling in Cancer.

Authors:  Laura M Campbell; Pamela J Maxwell; David J J Waugh
Journal:  Pharmaceuticals (Basel)       Date:  2013-08-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.